BRPI0711857A2 - 4-amino-pirido[3,2-e]pirazinas, uso das mesmas como inibidores de fosfodiestrase 10 e processo para a preparação das mesmas - Google Patents

Info

Publication number

BRPI0711857A2

BRPI0711857A2 BRPI0711857-0A BRPI0711857A BRPI0711857A2 BR PI0711857 A2 BRPI0711857 A2 BR PI0711857A2 BR PI0711857 A BRPI0711857 A BR PI0711857A BR PI0711857 A2 BRPI0711857 A2 BR PI0711857A2

Authority

BR

Brazil

Prior art keywords

disorders

alkyl

methyl

pyrido

amino

Prior art date

2006-05-30

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002360 preparation method Methods 0.000 title claims abstract description 26
• 238000000034 method Methods 0.000 title claims abstract description 16
• 230000008569 process Effects 0.000 title claims abstract description 11
• 239000003112 inhibitor Substances 0.000 title abstract description 13
• MKSOJXSIFTVEIO-UHFFFAOYSA-N 3h-pyrido[2,3-b]pyrazin-4-amine Chemical class C1=CN=C2N(N)CC=NC2=C1 MKSOJXSIFTVEIO-UHFFFAOYSA-N 0.000 title abstract description 4
• 150000001875 compounds Chemical class 0.000 claims abstract description 93
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 62
• 208000035475 disorder Diseases 0.000 claims abstract description 52
• 208000028017 Psychotic disease Diseases 0.000 claims abstract description 48
• 208000024891 symptom Diseases 0.000 claims abstract description 24
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract description 20
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract description 20
• 201000010099 disease Diseases 0.000 claims abstract description 10
• 208000020016 psychiatric disease Diseases 0.000 claims abstract description 7
• 230000007278 cognition impairment Effects 0.000 claims abstract description 6
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 4
• 208000025966 Neurological disease Diseases 0.000 claims abstract description 4
• 230000000926 neurological effect Effects 0.000 claims abstract description 4
• -1 cyclic radical Chemical class 0.000 claims description 108
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 64
• 125000005843 halogen group Chemical group 0.000 claims description 56
• 125000000217 alkyl group Chemical group 0.000 claims description 41
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims description 17
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
• 125000003118 aryl group Chemical group 0.000 claims description 15
• 206010026749 Mania Diseases 0.000 claims description 14
• 239000000203 mixture Substances 0.000 claims description 14
• 201000000980 schizophrenia Diseases 0.000 claims description 13
• 238000006243 chemical reaction Methods 0.000 claims description 11
• 208000013403 hyperactivity Diseases 0.000 claims description 11
• 208000019901 Anxiety disease Diseases 0.000 claims description 10
• 208000019022 Mood disease Diseases 0.000 claims description 10
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 9
• 230000005764 inhibitory process Effects 0.000 claims description 9
• 239000002904 solvent Substances 0.000 claims description 9
• 230000003542 behavioural effect Effects 0.000 claims description 8
• 208000010877 cognitive disease Diseases 0.000 claims description 8
• 229920006395 saturated elastomer Polymers 0.000 claims description 8
• 239000003814 drug Substances 0.000 claims description 7
• 208000028698 Cognitive impairment Diseases 0.000 claims description 6
• 208000024254 Delusional disease Diseases 0.000 claims description 6
• 208000020401 Depressive disease Diseases 0.000 claims description 6
• 208000012239 Developmental disease Diseases 0.000 claims description 6
• 208000014094 Dystonic disease Diseases 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
• 125000004122 cyclic group Chemical group 0.000 claims description 6
• 229910052739 hydrogen Inorganic materials 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 6
• 230000002085 persistent effect Effects 0.000 claims description 6
• 229910052717 sulfur Inorganic materials 0.000 claims description 6
• 206010012289 Dementia Diseases 0.000 claims description 5
• 208000016285 Movement disease Diseases 0.000 claims description 5
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 5
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
• 229910052801 chlorine Inorganic materials 0.000 claims description 5
• 125000005842 heteroatom Chemical group 0.000 claims description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 4
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
• 208000027691 Conduct disease Diseases 0.000 claims description 4
• 206010012559 Developmental delay Diseases 0.000 claims description 4
• 208000012661 Dyskinesia Diseases 0.000 claims description 4
• 208000027534 Emotional disease Diseases 0.000 claims description 4
• 208000023105 Huntington disease Diseases 0.000 claims description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
• 150000001204 N-oxides Chemical class 0.000 claims description 4
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 4
• 208000024791 Schizotypal Personality disease Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 125000002883 imidazolyl group Chemical group 0.000 claims description 4
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
• 230000013016 learning Effects 0.000 claims description 4
• 230000015654 memory Effects 0.000 claims description 4
• 125000002757 morpholinyl group Chemical group 0.000 claims description 4
• 208000022821 personality disease Diseases 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 125000004193 piperazinyl group Chemical group 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
• YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims description 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
• 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• 206010029333 Neurosis Diseases 0.000 claims description 3
• 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims description 3
• 206010041250 Social phobia Diseases 0.000 claims description 3
• 239000013543 active substance Substances 0.000 claims description 3
• 150000001412 amines Chemical class 0.000 claims description 3
• 210000004227 basal ganglia Anatomy 0.000 claims description 3
• 229910052799 carbon Inorganic materials 0.000 claims description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
• 208000015114 central nervous system disease Diseases 0.000 claims description 3
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
• 208000010118 dystonia Diseases 0.000 claims description 3
• 206010015037 epilepsy Diseases 0.000 claims description 3
• 125000000623 heterocyclic group Chemical group 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
• 208000008811 Agoraphobia Diseases 0.000 claims description 2
• 206010001540 Akathisia Diseases 0.000 claims description 2
• 208000036640 Asperger disease Diseases 0.000 claims description 2
• 201000006062 Asperger syndrome Diseases 0.000 claims description 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
• 208000020925 Bipolar disease Diseases 0.000 claims description 2
• 206010006362 Brief psychotic disorder, with postpartum onset Diseases 0.000 claims description 2
• 101100516554 Caenorhabditis elegans nhr-5 gene Chemical group 0.000 claims description 2
• 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 2
• 206010012218 Delirium Diseases 0.000 claims description 2
• 208000032538 Depersonalisation Diseases 0.000 claims description 2
• 206010012422 Derealisation Diseases 0.000 claims description 2
• 206010013654 Drug abuse Diseases 0.000 claims description 2
• 208000030814 Eating disease Diseases 0.000 claims description 2
• 208000000271 Encopresis Diseases 0.000 claims description 2
• 206010015605 Excessive masturbation Diseases 0.000 claims description 2
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
• 208000001836 Firesetting Behavior Diseases 0.000 claims description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
• 208000031886 HIV Infections Diseases 0.000 claims description 2
• 206010021030 Hypomania Diseases 0.000 claims description 2
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
• 208000020358 Learning disease Diseases 0.000 claims description 2
• 208000036626 Mental retardation Diseases 0.000 claims description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
• 206010057342 Onychophagia Diseases 0.000 claims description 2
• 229910020667 PBr3 Inorganic materials 0.000 claims description 2
• 229910020656 PBr5 Inorganic materials 0.000 claims description 2
• 229910019201 POBr3 Inorganic materials 0.000 claims description 2
• 206010033799 Paralysis Diseases 0.000 claims description 2
• 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
• 101710122057 Phospholemman-like protein Proteins 0.000 claims description 2
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 claims description 2
• 208000005793 Restless legs syndrome Diseases 0.000 claims description 2
• 206010039987 Senile psychosis Diseases 0.000 claims description 2
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
• 208000027520 Somatoform disease Diseases 0.000 claims description 2
• 206010073746 Thumb sucking Diseases 0.000 claims description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
• 206010046543 Urinary incontinence Diseases 0.000 claims description 2
• 230000006978 adaptation Effects 0.000 claims description 2
• 230000003044 adaptive effect Effects 0.000 claims description 2
• 239000002671 adjuvant Substances 0.000 claims description 2
• 230000016571 aggressive behavior Effects 0.000 claims description 2
• 230000036506 anxiety Effects 0.000 claims description 2
• 208000029560 autism spectrum disease Diseases 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 230000005978 brain dysfunction Effects 0.000 claims description 2
• 229960001948 caffeine Drugs 0.000 claims description 2
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
• 229930003827 cannabinoid Natural products 0.000 claims description 2
• 239000003557 cannabinoid Substances 0.000 claims description 2
• 229940065144 cannabinoids Drugs 0.000 claims description 2
• 206010007776 catatonia Diseases 0.000 claims description 2
• 229960003920 cocaine Drugs 0.000 claims description 2
• SOEZHGVDTFXVOU-UHFFFAOYSA-N cyclopropyl-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)carbamic acid Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N(C(O)=O)C1CC1 SOEZHGVDTFXVOU-UHFFFAOYSA-N 0.000 claims description 2
• 208000026725 cyclothymic disease Diseases 0.000 claims description 2
• 230000006378 damage Effects 0.000 claims description 2
• 230000001419 dependent effect Effects 0.000 claims description 2
• 230000003001 depressive effect Effects 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 235000014632 disordered eating Nutrition 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 206010013932 dyslexia Diseases 0.000 claims description 2
• 208000024732 dysthymic disease Diseases 0.000 claims description 2
• 230000001505 hypomanic effect Effects 0.000 claims description 2
• 208000015181 infectious disease Diseases 0.000 claims description 2
• 201000003723 learning disability Diseases 0.000 claims description 2
• 208000024714 major depressive disease Diseases 0.000 claims description 2
• 206010027175 memory impairment Diseases 0.000 claims description 2
• 230000003340 mental effect Effects 0.000 claims description 2
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
• 229940005483 opioid analgesics Drugs 0.000 claims description 2
• 208000021090 palsy Diseases 0.000 claims description 2
• 208000019906 panic disease Diseases 0.000 claims description 2
• YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 claims description 2
• UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 claims description 2
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 claims description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
• 208000021011 postpartum psychosis Diseases 0.000 claims description 2
• 230000000750 progressive effect Effects 0.000 claims description 2
• 230000001003 psychopharmacologic effect Effects 0.000 claims description 2
• 201000004645 pyromania Diseases 0.000 claims description 2
• 230000000306 recurrent effect Effects 0.000 claims description 2
• 125000006413 ring segment Chemical group 0.000 claims description 2
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
• 230000001568 sexual effect Effects 0.000 claims description 2
• 239000000021 stimulant Substances 0.000 claims description 2
• 208000011117 substance-related disease Diseases 0.000 claims description 2
• 208000011580 syndromic disease Diseases 0.000 claims description 2
• 230000001052 transient effect Effects 0.000 claims description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
• 230000002140 halogenating effect Effects 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
• 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
• 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
• 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 1
• 238000010494 dissociation reaction Methods 0.000 claims 1
• 230000005593 dissociations Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
• 208000015238 neurotic disease Diseases 0.000 claims 1
• 230000035946 sexual desire Effects 0.000 claims 1
• 208000018724 torsion dystonia Diseases 0.000 claims 1
• 230000000694 effects Effects 0.000 abstract description 21
• 210000003169 central nervous system Anatomy 0.000 abstract description 3
• 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
• 235000002639 sodium chloride Nutrition 0.000 description 18
• 241000700159 Rattus Species 0.000 description 17
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 13
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
• 125000004432 carbon atom Chemical group C* 0.000 description 10
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 10
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• 241000282898 Sus scrofa Species 0.000 description 9
• ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 9
• 108090000623 proteins and genes Proteins 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 241000700199 Cavia porcellus Species 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 235000014113 dietary fatty acids Nutrition 0.000 description 8
• 239000000194 fatty acid Substances 0.000 description 8
• 229930195729 fatty acid Natural products 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 7
• 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 7
• 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 7
• 239000000543 intermediate Substances 0.000 description 7
• 210000001577 neostriatum Anatomy 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000000164 antipsychotic agent Substances 0.000 description 6
• 239000000460 chlorine Chemical group 0.000 description 6
• 230000006735 deficit Effects 0.000 description 6
• 239000003999 initiator Substances 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 5
• 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 230000003291 dopaminomimetic effect Effects 0.000 description 5
• 229960003878 haloperidol Drugs 0.000 description 5
• 239000001257 hydrogen Substances 0.000 description 5
• 239000002858 neurotransmitter agent Substances 0.000 description 5
• 229960001789 papaverine Drugs 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 4
• NAXIXAPHUQGPPU-UHFFFAOYSA-N N1=CC2=CN=CN2C2=C1C=CC(=O)N2 Chemical class N1=CC2=CN=CN2C2=C1C=CC(=O)N2 NAXIXAPHUQGPPU-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
• 230000003950 pathogenic mechanism Effects 0.000 description 4
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
• 229950010883 phencyclidine Drugs 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
• OLSVMVKBHIDCMX-UHFFFAOYSA-N 4-amino-1-ethyl-8-methoxy-3-methyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2N OLSVMVKBHIDCMX-UHFFFAOYSA-N 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 235000010419 agar Nutrition 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 230000000561 anti-psychotic effect Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 230000000848 glutamatergic effect Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• 235000010981 methylcellulose Nutrition 0.000 description 3
• 239000001923 methylcellulose Substances 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 3
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000037452 priming Effects 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 125000005624 silicic acid group Chemical class 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• DCBOUXKSNFDXER-UHFFFAOYSA-N 1h-pyrido[2,3-b]pyrazin-2-one Chemical class C1=CC=C2NC(=O)C=NC2=N1 DCBOUXKSNFDXER-UHFFFAOYSA-N 0.000 description 2
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• KFRDNUKGRRHJCL-UHFFFAOYSA-N 4-chloro-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2Cl KFRDNUKGRRHJCL-UHFFFAOYSA-N 0.000 description 2
• JCESMQJJGPDXAO-UHFFFAOYSA-N 4-methoxy-11-methyl-13-phenyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)N)=C2N1C1=CC=CC=C1 JCESMQJJGPDXAO-UHFFFAOYSA-N 0.000 description 2
• FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 101150049660 DRD2 gene Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 229920002907 Guar gum Polymers 0.000 description 2
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 235000011054 acetic acid Nutrition 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
• 229960004046 apomorphine Drugs 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical class CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical class CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 235000010417 guar gum Nutrition 0.000 description 2
• 239000000665 guar gum Substances 0.000 description 2
• 229960002154 guar gum Drugs 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
• VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
• 201000001881 impotence Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 229920000151 polyglycol Polymers 0.000 description 2
• 239000010695 polyglycol Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 230000000698 schizophrenic effect Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 229920002545 silicone oil Polymers 0.000 description 2
• 229910052938 sodium sulfate Inorganic materials 0.000 description 2
• 235000011152 sodium sulphate Nutrition 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 230000003936 working memory Effects 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
• OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• WTGVJERCTXWBLZ-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-hydroxybenzoic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C1=CC=CC=C1O WTGVJERCTXWBLZ-BTJKTKAUSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• IQWHMQXYQFMONQ-UHFFFAOYSA-N 10-bromo-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaene Chemical class N1=CC2=CN=CN2C2=C1C(Br)=CC=N2 IQWHMQXYQFMONQ-UHFFFAOYSA-N 0.000 description 1
• WXHUPSIMAWTGSO-UHFFFAOYSA-N 11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10-pentaen-10-amine Chemical compound N1=CC2=CN=CN2C2=C1C(N)=C(C)CN2CCC WXHUPSIMAWTGSO-UHFFFAOYSA-N 0.000 description 1
• XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 1
• XSUZWGLUKSVWPV-UHFFFAOYSA-N 13-(2-chlorophenyl)-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)N)=C2N1C1=CC=CC=C1Cl XSUZWGLUKSVWPV-UHFFFAOYSA-N 0.000 description 1
• SMRXDCQNQAWEJF-UHFFFAOYSA-N 13-ethyl-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10-pentaen-10-amine Chemical compound N1=CC2=CN=CN2C2=C1C(N)=C(C)CN2CC SMRXDCQNQAWEJF-UHFFFAOYSA-N 0.000 description 1
• KBCZMCBZVDVOGT-UHFFFAOYSA-N 13-ethyl-4-(2-ethyl-4-methylimidazol-1-yl)-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound CCN1CC(C)=C(N)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CC KBCZMCBZVDVOGT-UHFFFAOYSA-N 0.000 description 1
• ZUPYWPRIHYBHOV-UHFFFAOYSA-N 13-hexyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCCCCC)CC(C)=C2N ZUPYWPRIHYBHOV-UHFFFAOYSA-N 0.000 description 1
• LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
• OAWAZQITIZDJRB-UHFFFAOYSA-N 2-chloro-2,2-difluoroacetic acid Chemical compound OC(=O)C(F)(F)Cl OAWAZQITIZDJRB-UHFFFAOYSA-N 0.000 description 1
• ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
• PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical compound NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
• ZVKSPJQJCVSXIP-UHFFFAOYSA-N 4-amino-8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N ZVKSPJQJCVSXIP-UHFFFAOYSA-N 0.000 description 1
• DOGGHPLCFFBQPV-UHFFFAOYSA-N 4-chloro-3-methyl-1-propyl-9h-imidazo[1,5-a]pyrido[3,2-e]pyrazin-8-ol Chemical compound N12CN(O)C=C2C=NC2=C1N(CCC)CC(C)=C2Cl DOGGHPLCFFBQPV-UHFFFAOYSA-N 0.000 description 1
• HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical class CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• ZEOVQWMIURTGNO-UHFFFAOYSA-N 4-hydroxy-10-imidazol-1-yl-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(O)C=C2C=NC2=C1N(CCC)CC(C)=C2N1C=CN=C1 ZEOVQWMIURTGNO-UHFFFAOYSA-N 0.000 description 1
• 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
• KESPCZOUAZTDHV-UHFFFAOYSA-N 4-methoxy-N,N,11-trimethyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-amine Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N(C)C KESPCZOUAZTDHV-UHFFFAOYSA-N 0.000 description 1
• 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• DGAUZHDBLDRYQF-UHFFFAOYSA-N 8-methoxy-3-methyl-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine-4-one Chemical compound N1=CC2=CN(OC)CN2C2=C1C(=O)C(C)=CN2CCC DGAUZHDBLDRYQF-UHFFFAOYSA-N 0.000 description 1
• 201000010000 Agranulocytosis Diseases 0.000 description 1
• POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 229920000945 Amylopectin Polymers 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 235000021357 Behenic acid Nutrition 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
• XKUDEHUNXUKIIB-UHFFFAOYSA-N C(C)(=O)N(C(C)=O)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.C(C)(=O)NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C Chemical compound C(C)(=O)N(C(C)=O)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.C(C)(=O)NC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C XKUDEHUNXUKIIB-UHFFFAOYSA-N 0.000 description 1
• BZXCTTUNRCHYSO-UHFFFAOYSA-N C1=CN=C2N3C=NC=C3C=NC2=C1 Chemical class C1=CN=C2N3C=NC=C3C=NC2=C1 BZXCTTUNRCHYSO-UHFFFAOYSA-N 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000009132 Catalepsy Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
• 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
• 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000027776 Extrapyramidal disease Diseases 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 108091006101 Gi proteins Proteins 0.000 description 1
• 102000034354 Gi proteins Human genes 0.000 description 1
• 108091006065 Gs proteins Proteins 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 206010020852 Hypertonia Diseases 0.000 description 1
• 206010021703 Indifference Diseases 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• BEUJZQNSJWHYCC-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)acetamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NC(C)=O BEUJZQNSJWHYCC-UHFFFAOYSA-N 0.000 description 1
• ZGJIWKUAVAJRLF-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)formamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NC=O ZGJIWKUAVAJRLF-UHFFFAOYSA-N 0.000 description 1
• 229940095474 NMDA agonist Drugs 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 208000027626 Neurocognitive disease Diseases 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
• HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000028810 Shared psychotic disease Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 241000282890 Sus Species 0.000 description 1
• 241000282896 Sus sp. Species 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 238000010162 Tukey test Methods 0.000 description 1
• 206010047853 Waxy flexibility Diseases 0.000 description 1
• CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000036626 alertness Effects 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 229960000458 allantoin Drugs 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 239000010775 animal oil Substances 0.000 description 1
• 230000003266 anti-allergic effect Effects 0.000 description 1
• 230000001088 anti-asthma Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000000924 antiasthmatic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229940116226 behenic acid Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
• 229940073608 benzyl chloride Drugs 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 230000009045 body homeostasis Effects 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 238000010805 cDNA synthesis kit Methods 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920003086 cellulose ether Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 125000001309 chloro group Chemical class Cl* 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical class CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 229960002380 dibutyl phthalate Drugs 0.000 description 1
• 229940031578 diisopropyl adipate Drugs 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
• 229950004794 dizocilpine Drugs 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000003073 embolic effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000007824 enzymatic assay Methods 0.000 description 1
• DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 150000002169 ethanolamines Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229940116333 ethyl lactate Drugs 0.000 description 1
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 229920006158 high molecular weight polymer Polymers 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• WGYMXASRWCYKQR-UHFFFAOYSA-N imidazo[1,5-a]quinoxaline Chemical class C1=CC=C2N3C=NC=C3C=NC2=C1 WGYMXASRWCYKQR-UHFFFAOYSA-N 0.000 description 1
• HOFSPGAYXKNFAM-UHFFFAOYSA-N imidazo[4,5-f]quinoxalin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=N1 HOFSPGAYXKNFAM-UHFFFAOYSA-N 0.000 description 1
• 150000005235 imidazopyrazines Chemical class 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 229910052740 iodine Chemical group 0.000 description 1
• 239000011630 iodine Chemical group 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 229940089456 isopropyl stearate Drugs 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 208000011977 language disease Diseases 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000001055 magnesium Nutrition 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 229920003087 methylethyl cellulose Polymers 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229910052901 montmorillonite Inorganic materials 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 150000002780 morpholines Chemical class 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
• SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 230000005015 neuronal process Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Chemical class CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
• BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical class CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000010915 one-step procedure Methods 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• 230000008288 physiological mechanism Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 238000004237 preparative chromatography Methods 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
• 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
• 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 238000005956 quaternization reaction Methods 0.000 description 1
• SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000003352 sequestering agent Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 230000003997 social interaction Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 229940023144 sodium glycolate Drugs 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 125000001302 tertiary amino group Chemical group 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 210000001103 thalamus Anatomy 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 125000002640 tocopherol group Chemical class 0.000 description 1
• 235000019149 tocopherols Nutrition 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000000304 vasodilatating effect Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1